By Rick Pezzullo– Tarrytown-based Regeneron Pharmaceuticals, Inc. announced Monday the initiation of late-stage clinical trials evaluating REGN-COV2, the company’s investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2’s ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient and is being run jointly with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). REGN-COV2 has also moved into the [...]
The post Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial appeared first on The Hudson Independent.